Phuturdex › Diseases › Skin disease
Drugs in development · updated 30 October 2026
Skin disease: drugs in development
As of 30 October 2026 there are 34 active clinical trials (recruiting or ongoing, phases I–III) on 34 drugs for skin disease. 16 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Sonelokimab | III | 2 | NCT07007637 |
| TilrekimigPF-07275315 | III | 2 | NCT07783425 |
| IMG-007 | II | 2 | NCT07037901 |
| Tibulizumab | II | 2 | NCT06993610 |
| Bezuclastinib TabletsCGT9486 | II | 1 | NCT04996875 |
| Camoteskimab | II | 1 | NCT07599813 |
| LAD328 | II | 1 | NCT07547813 |
| Oral Ifetroban | II | 1 | NCT02682511 |
| SPY072 | II | 1 | NCT07766005 |
| BG-A3004 | I | 1 | NCT07412691 |
| BMS-986515 | I | 1 | NCT07115745 |
| DibotatugDR-01 | I | 1 | NCT06602232 |
| GTX-B001 | I | 1 | NCT07181369 |
| HL40626S | I | 1 | NCT07736586 |
| DiphenylcyclopropenoneDiphencyprone | Early I | 1 | NCT05020496 |
| KB111 | Early I | 1 | NCT07717346 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DupilumabDUPIXENT | III | 3 | NCT07783425 |
| LebrikizumabEbglyss® | III | 3 | NCT07542483 |
| RuxolitinibJakavi, Jakafi Xr® | III | 3 | NCT06959225 |
| AnastrozoleAnastrozol, Anastrazole | III | 1 | NCT04711252 |
| BaricitinibOlumiant® | III | 1 | NCT05723198 |
| CamizestrantAZD9833, Etcamah® | III | 1 | NCT04711252 |
| PalbociclibPabociclib, Palbocicilib | III | 1 | NCT04711252 |
| BimekizumabBimzelx® | II | 1 | NCT07766005 |
| CephalexinKeftab®, Keflet® | II | 1 | NCT01631617 |
| DoxycyclineDoxycyclin, Lymepak® | II | 1 | NCT01631617 |
| GuselkumabTremfya | II | 1 | NCT06563323 |
| MethoxsalenUvadex, Oxsoralen-Ultra® | II | 1 | NCT04986605 |
| Shingrix | II | 1 | NCT07205796 |
| SulfamethoxazoleGantanol®, Gantanol-Ds® | II | 1 | NCT01631617 |
| TrimethoprimPrimsol®, Trimpex 200® | II | 1 | NCT01631617 |
Sorted by most advanced phase and number of active trials. Showing 15 of 18 drugs.
All 34 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Breast neoplasm 593 drugs
- Melanoma 352 drugs
- Triple-negative breast neoplasm 334 drugs
- Non-small-cell lung carcinoma 726 drugs
- Ovarian neoplasm 411 drugs
- Metastasis 493 drugs
- Colorectal neoplasm 534 drugs
- Head and neck squamous cell carcinoma 321 drugs
- Atopic dermatitis 91 drugs
- Neoplasm 671 drugs
- Stomach neoplasm 340 drugs
- Endometrial neoplasm 298 drugs
Broader categories
- Skin and connective tissue diseases 3 drugs
- Genetic disease 33 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Bacterial Infections 16 drugs
- Hypersensitivity 22 drugs
- Infection 71 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D012871 “Skin Diseases”.